A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Protocol No
ASTELLAS-8374-CL-0101
Principal Investigator
Stuart Wong
Phase
I
Summary
ASP8374 is an investigational drug that is being studied to treat advanced (unresectable) or metastatic tumors. ASP8374 targets the TIGIT receptor which is found on some cells of the immune system. TIGIT acts to turn off the immune system after it has been activated. By inhibiting the TIGIT receptor, ASP8374 may help your immune system to fight your tumor. As an immune checkpoint inhibitor, ASP8374 may take the brakes off the immune system and help the immune system to attack tumor cells. Pembrolizumab is an immunotherapy and it works with your immune system to help fight cancer. It's an antibody that blocks the mechanism by which cancer cells protect themselves and allows your body's immune system to destroy those cancer cells.
Description
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: